Evidence map›Paper›PMID 38820252›Full record

ArticlePloS one2024

Dysregulation of miR-122, miR-574 and miR-375 in Egyptian patients with breast cancer.

Eman A Elghoroury, Esmat E Abdelghafar, Solaf Kamel, Eman Awadallah, Aliaa Shalaby, Gamila S M El-Saeed, Eman Mahmoud, Mahmoud M Kamel, Asmaa Abobakr, Rasha Nazih Yousef

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eman A ElghorouryDepartment of Clinical & Chemical Pathology, Medical Research and Clinical Studies Institute, National Research Center, Giza, Egypt.
Esmat E AbdelghafarDepartment of Clinical & Chemical Pathology, Medical Research and Clinical Studies Institute, National Research Center, Giza, Egypt.
Solaf KamelDepartment of Clinical & Chemical Pathology, Medical Research and Clinical Studies Institute, National Research Center, Giza, Egypt.
Eman AwadallahDepartment of Clinical & Chemical Pathology, Medical Research and Clinical Studies Institute, National Research Center, Giza, Egypt.
Aliaa ShalabyDepartment of Clinical & Chemical Pathology, Medical Research and Clinical Studies Institute, National Research Center, Giza, Egypt.
Gamila S M El-SaeedMedical Biochemistry, Medical Research and Clinical Studies Institute, National Research Center, Giza, Egypt.
Eman MahmoudDepartment of Clinical & Chemical Pathology, Medical Research and Clinical Studies Institute, National Research Center, Giza, Egypt.
Mahmoud M KamelClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.ORCID 0000-0003-0264-3096
Asmaa AbobakrClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Rasha Nazih YousefDepartment of Clinical & Chemical Pathology, Medical Research and Clinical Studies Institute, National Research Center, Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe early detection of breast cancer (BC) is receiving global attention, creating an urgent need for more sensitive and comprehensive strategies for preventive intervention, therapy assessment, and prognosis prediction. Aberrant expression of miRNAs has been observed in various malignancies and may be potential targets for therapy. Our study aims to examine the expression profiles of miR-375, miR-574-3p, and miR-122 in the sera of Egyptian women with BC, benign breast lesions, and a control group. We hope to determine if these miRNAs can serve as minimally invasive biomarkers for BC.

methodsThis is a case-control study in which 77 patients with newly diagnosed BC, 20 patients with benign breast tumors, and 30 normal healthy subjects as controls were recruited from the outpatient clinic of the National Cancer Institute. The assessment of miRNAs was conducted using RT-PCR (Applied Biosystems).

resultsThe expression level of miRNA-122 was significantly upregulated in the BC group, while the expression levels of miRNA-574 and miRNA-375 showed significant downregulation in BC patients. Serum miR-122 and miRNA-375 were able to distinguish breast cancer from the benign and control groups in ROC curve analysis, with AUCs of 0.786 and 0.796, respectively. Our results also showed that serum miR-122 and miR-574 are significant predictor variables in the multivariate analysis, after adjusting for age.

conclusionsOur findings suggest that miR-122 may act as an onco-microRNA, while miR-574 and miR-375 may have a main tumour suppressor role. The studied miRNAs may serve as minimally invasive biomarkers for cases of breast cancer and as promising potential therapeutic targets for breast cancer.

Indexed as

Biomarkers, TumorBreast NeoplasmsMicroRNAsAdultAgedCase-Control StudiesEgyptFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedROC CurveBiomarkers, TumorMicroRNAsMIRN122 microRNA, humanMIRN375 microRNA, humanMIRN574 microRNA, human

Identifiers

PMID38820252
PMCPMC11142443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.